Rilzabrutinib is under clinical development by and currently in Phase II for Immunoglobulin G4-Related Disease (IgG4-RD). According to GlobalData, Phase II drugs for Immunoglobulin G4-Related Disease (IgG4-RD) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Rilzabrutinib LoA Report.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rilzabrutinib overview
Rilzabrutinib (PRN-1008) is under development for the treatment of autoimmune hemolytic anemia, immune thrombocytopenic purpura, asthma, Chronic spontaneous urticaria, atopic dermatitis, purigo nodularis and IgG4-related disease. The drug candidate is a small molecule administered orally. The drug candidate targets Bruton's tyrosine kinase (BTK) enzyme. It is based on Tailored covalency technology platform. It was also under development for rheumatoid arthritis, systemic lupus erythematosus (SLE) and inflammatory bowel disease.
Rilzabrutinib was under development for the treatment of pemphigus foliaceus, newly diagnosed or relapsing pemphigus vulgaris,
Sanofi overview
is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women鈥檚 health; and vitamins, minerals, and supplements. ‘s R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa, and the Middle East. is headquartered in Paris, Ile-de-France, France.
For a complete picture of Rilzabrutinib’s drug-specific PTSR and LoA scores,
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData鈥檚 unrivalled proprietary data will enable you to decode what鈥檚 happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
